Alzamend Neuro (ALZN): A Name to Watch as it approaches a critical clinical milestone. The company's lead program, AL001, is designed to deliver lithium more effectively to the brain while reducing systemic toxicity, a potential turning point in treatment options for Alzheimer's and mood disorders.
This clinical-stage biopharmaceutical company advances therapies for Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). With AL001 progressing through Phase II studies, the company is aiming to solve long-standing challenges in lithium therapy. The upcoming topline data in early 2026 could serve as a pivotal catalyst, positioning ALZN as a noteworthy player in the small-cap biotech space.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.